Treatment possibilities of ipilimumab-induced thrombocytopenia-case study and literaure review

Abstrakt

Recently, new drugs targeting the immune system have been introduced to the standard care of metastatic malignant melanoma. One of these immunomodulatory drugs is ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4.

The following case reports on a 54-year-old man with metastatic melanoma, who developed Grade 4 thrombocytopenia during treatment with ipilimumab already after first dose.

Klíčová slova

• ipilimumab
• melanoma
• thrombocytopenia